This Insight Pharma Report discusses leading-edge strategies to improve R&D productivity in the pharmaceutical and biotechnology industry, which is arguably the central challenge in the industry today. These strategies, which focus on translational medicine, are aimed at lowering R&D costs and enabling the industry to successfully develop innovative drugs that address unmet medical needs. The report also includes an analysis of the results of an industry survey on strategies to improve R&D productivity, and complete transcripts of expert interviews.
For more information on the report, or to order it, see the CHI Insight Pharma Reports website.
Approaches to Reducing Phase II Attrition
Alan Haberman holds a Ph.D. in biochemistry and molecular biology from Harvard University and has an extensive background in the pharmaceutical and biotechnology industry.
More on the author.
*Report is available for single user.